Bioanalysis of Cannabinoids

Around 144 cannabinoids have been identified in cannabis plant, among them tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prominent ones. The market for cannabis and cannabinoids has experienced significant growth in recent years, driven by a combination of changing regulatory landscapes, increasing consumer demand and growing recognition of the potential health and wellness benefits associated with these compounds. As a cutting-edge laboratory, ABF is at the forefront of this scientific journey and has already developed methods for the bioanalysis of cannabis and cannabinoids. These methods are characterized by its level of sensitivity, automation, throughput and can be used for pharmacokinetic studies, exposure assessment and risk evaluation.

Our Commitment

check icon

Extensive expertise in the analysis of biological samples for both clinical and non-clinical studies

check icon

Uncompromising Quality, Compliance, and Data Integrity

check icon

Timely and Accurate Analysis & Reporting Supporting Decision-Making and Research Efforts

Request now
cannabinoid

Cutting-Edge Cannabinoid Quantification Services

Trusted Bioanalytical Services Tailored to Your Specific Application

Integrated Solutions for Seamless Sample Management World Wide

Biomarker
Exposure to
Matrix
Analytical Technique
Reference
6-Hydroxycannabidiol (6-OH-CBD) Cannabidiol Plasma LC-MS/MS
7-Carboxycannabidiol (7-COOH-CBD) Cannabidiol Plasma LC-MS/MS
7-Hydroxycannabidiol (7-OH-CBD) Cannabidiol Plasma LC-MS/MS
Cannabidiol (CBD) Cannabidiol Plasma LC-MS/MS
Creatinine Normalization of urinary biomarker concentrations Urine Photometry

Pioneers in biomarker research

Almost all of the biomarker methods developed at ABF were published in peer-reviewed journals, a fact that supports the validity, transparency and scientific evidence of the bioanalysis especially of importance for regulatory submissions